Cell Genesys (CEGE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (1110)	5/3/2001 1:48:17 AM
From: Londo	of 1298

The argument that Jim McCamant brings with the link is the standard "Buy CEGE because of its overwhelmingly strong balance sheet that values its operations at zero" argument. The only real catalyst for CEGE to head higher is that GVAX will have to be successful. The two lead GVAX candidates are for the Prostate and Pancreatic indications. Prostate: They are testing a 'high potency' (5-10x more powerful) GVAX in a Phase I/II clinical that should yield results by mid 2002. This is timed precisely as such because their new manufacturing plant (they will spend $50-$60M building it) will be able to make GVAX product for Phase III and market launch. If successful, they are planning for it to be more effective than chemotherapy.. or to be used in combination with chemotherapy to increase the mean time to progression statistically signifigantly higher than just plain chemotherapy alone (without all of the nasty side effects of chemo in the event of GVAX-only treatment). Pancreatic: Based on Phase I results which allegedly yielded 3 patients (out of 7 or something) that are still 30 months+ with disease-free survival. Obviously if these results can be statistically extrapolated to a larger population, CEGE will be in complete business. So they are doing a Phase II trial to see if this is a statistical fluke or not. If it turns out not to be a statistical fluke, GVAX Pancreatic will be sent through the FDA so quickly, it won't be funny. These are the only two events on the seeable horizon that can give a jump to CEGE's stock price to something significantly higher than their per-share book value. For the record, I own some CEGE, mainly because I think their business plan is realistic, and they've done an excellent job managing their cash horde. A dot-com would have burned through it in a few months. :)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next